Clinical Trial Update: A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating oral atogepant for migraine prevention in Japanese participants with chronic or episodic migraine has completed and results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Episodic Migraine
• Migraine

Drugs mentioned

• Qulipta (atogepant)

Snippet

Sponsor: AbbVie | Conditions: Chronic Migraine, Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2025-07-22